Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 13.11 HKD 2.66% Market Closed
Market Cap: 34B HKD

EV/EBITDA
Enterprise Value to EBITDA

22.7
Current
17.3
Median
13.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
22.7
=
Enterprise Value
30.8B HKD
/
EBITDA
1.2B CNY
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
17.2
2-Years Forward
EV/EBITDA
12.5
3-Years Forward
EV/EBITDA
12.6